Literature DB >> 34989831

Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis.

Fabio Barra1,2, Lorenzo Ferro Desideri3,4, Claudio Gustavino5, Simone Ferrero6,3, Carlo Enrico Traverso3,4, Massimo Nicolò3,4.   

Abstract

Correspondence to the original research entitled "Effects of ranibizumab and zoledronic acid on endometriosis in a rat model" published by Ozdemir et al.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Endometriosis; Medical therapy; Ranibizumab; Rat model; Zoledronic acid

Mesh：

Substances：

Year:  2022        PMID： 34989831     DOI： 10.1007/s00404-021-06390-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.493


  2 in total

Review 1.  Quality of life in women with endometriosis: a narrative overview.

Authors:  Valentina L La Rosa; Pasquale De Franciscis; Fabio Barra; Antonio Schiattarella; Péter Török; Mohsin Shah; Erbil Karaman; Tais Marques Cerentini; Federica Di Guardo; Giuseppe Gullo; Marco Ponta; Simone Ferrero
Journal:  Minerva Med       Date:  2019-11-12       Impact factor: 4.806

2.  Effects of ranibizumab and zoledronic acid on endometriosis in a rat model.

Authors:  Eda Ureyen Ozdemir; Ertan Adali; Mine Islimye Taskin; Altug Yavasoglu; Huseyin Aktug; Fatih Oltulu; Umit Inceboz
Journal:  Arch Gynecol Obstet       Date:  2021-06-03       Impact factor: 2.493
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.